| (19) |
 |
|
(11) |
EP 2 860 192 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
22.04.2015 Bulletin 2015/17 |
| (43) |
Date of publication A2: |
|
15.04.2015 Bulletin 2015/16 |
| (22) |
Date of filing: 12.10.2006 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE
SI SK TR |
|
Designated Extension States: |
|
AL BA HR MK RS |
| (30) |
Priority: |
12.10.2005 US 725297 P
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
06806243.9 / 1945671 |
| (71) |
Applicant: MorphoSys AG |
|
82152 Martinsried/München (DE) |
|
| (72) |
Inventors: |
|
- Tesar, Michael
86316 Friedberg (DE)
- Jäger, Ute
81667 München (DE)
|
| (74) |
Representative: Jones Day |
|
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München
80538 München (DE) |
|
| |
|
| (54) |
Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies
specific for human CD38 |
(57) The invention provides a human antibody that is specific for CD38. The antibody of
the invention has the ability to bind to CD38 of minipig origin and induce, by cross-linking,
specific killing of cells, in particular tumor cells, expressing CD38. The invention
further provides uses of this antibody for treating various disorders and conditions
associated with undesired presence of CD38+ cells, including hematological and inflammatory
diseases. The invention also provides diagnostic compositions and methods based on
detecting the presence of CD38 in a tissue or a cell of minipig origin contacted with
the antibody of the invention.